




# Release Testing

## Rapid, high-quality, cGMP-compliant

Release testing is a critical aspect of drug development, ensuring the safety, identity, purity, and potency of raw materials, drug substances (DS), and drug products (DP). From preclinical stages to commercial lot release, rigorous testing protocols with phase-appropriate validation must be employed to safeguard patient health and uphold confidence in the pharmaceutical supply chain:



Solvias has decades of experience performing excipient & raw materials, DS, and DP release testing for small molecules, biologics, and cell and gene therapies. We can help establish your CQAs and devise the right and minimum combination of tests to deliver the phase-appropriate results you need for release.




### Small Molecules

Full service with 10- to 15-day turnaround: identity, purity, impurities, potency, particulates, dissolution, bioavailability, and DS-excipients interactions.



### Biologics

Comprehensive solution for DS and DP batch release testing for monoclonal antibodies (mAb), bispecific antibodies, ADCs and other recombinant proteins.




### Cell & Gene Therapies

Release testing for viral vectors, from biophysical characterization of capsid proteins and stability testing, to potency and sterility testing for both *in vivo* and *ex vivo* CGTs.

## Why partner with us?

- CRO
- Founded in 1999
- 800+ team members
- 175+ PhD-level scientists
- GMP, GLP, ISO9001 certified
- 23K m<sup>2</sup> of lab capacity
- 700+ customers worldwide
- 5 centers of excellence



**Contact us to speak with  
an expert:** [info@solvias.com](mailto:info@solvias.com)

  [solvias.com](https://www.solvias.com)

